Received Jun 30, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| DTAPHEPBIP | DTAP + HEPB + IPV (PEDIARIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | 9D25P | — |
| HEPA | HEP A (HAVRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | 22GP3 | — |
administered PEDIARIX and HAVRIX to a patient who was already up to date with vaccinations; This non-serious case was reported by a other health professional via call center representative and described the occurrence of extra dose administered in a 2-year-old female patient who received DTPa-HBV-IPV (Pediarix) (batch number 9D25P, expiry date 25-OCT-2025) for prophylaxis. Co-suspect products included HAV (Havrix 720) (batch number 22GP3, expiry date 11-SEP-2026) for prophylaxis. On 20-JUN-2025, the patient received Pediarix and Havrix 720. On 20-JUN-2025, an unknown time after receiving Pediarix and Havrix 720, the patient experienced extra dose administered (Verbatim: administered PEDIARIX and HAVRIX to a patient who was already up to date with vaccinations). The outcome of the extra dose administered was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 20-JUN-2025 The medical assistant reports that she administered Pediarix and Havrix to a patient who was already up to date with vaccinations which led to extra dose administered. The patient did not need the vaccinations.